

## Guideline for the use of vitamin D in children and young people

Author Rachel Guy, paediatric pharmacist, STSFT and

Dr. Neil Hopper, consultant paediatrician, STSFT

Approved by South Tyneside and Sunderland Area Prescribing

Committee and relevant groups / committees

within stakeholder organisations

Current Version 1

Published on March 2021

Review date March 2024

**Version Control** 



## South Tyneside and Sunderland Area Prescribing Committee

## **Children and Young People's Vitamin D Guidelines**

12 years - adult	Deficiency	Insufficiency
	(<25 nmol/L	(25-50 nmol/L)
Oral treatment	Colecalciferol capsules (Invita D3) 50,000 IU once a week.	400-600 IU once a day (2 vitamin BPC capsules or equivalent OTC preparation)
IM/PO Stoss therapy (over 12 months)	Ergocalciferol 300,000 IU IM x1 (or colecalciferol 300,000 IU PO)	-

6 months – 11 years	Deficiency (<25 nmol/L)	Insufficiency (25-50 nmol/L)
Oral treatment	Colecalciferol 6000 IU / day. Give as Thorens (200 IU/drop - 10,000 IU/mL)	400-600 IU once a day (0.6mL Abidec* or equivalent OTC preparation)  *Abidec is contraindicated in peanut allergy - Dalivit 0.6ml is a peanut free alternative
IM/PO Stoss therapy (over 12 months)	Ergocalciferol 300,000 IU IM x1 (or colecalciferol 300,000 IU PO)	-

<6 months old	Deficiency	Insufficiency
	(<25 nmol/L)	(25-50 nmol/L)
Oral treatment	Colecalciferol 3000 IU / day.	400-600 IU once a day (0.6mL
	Give as Thorens (200 IU/drop - 10,000	Abidec*)
	IU/mL)	
		*Abidec is contraindicated in peanut
		allergy - Dalivit 0.6ml is a peanut
		free alternative
IM/PO Stoss therapy	Not usually recommended	-
(over 12 months)		

3 months of treatment is required at least for deficiency and this is to be carried out by a prescriber. Then consider 400-600 IU once a day in the long-term to prevent deficiency reoccurring, parents/guardians should be directed to purchase over-the-counter after this time.

Do not use multivitamins for higher doses. National Osteoporosis Society Guidelines

Authors: Rachel Guy (paediatric pharmacist, STSFT) and Dr Neil Hopper (STSFT) Feb 2021

Approved: March 2021 Review: March 2024